Technology Type

Therapeutic Modality

View all technologies

370 results

(0.12 seconds)

A Novel Approach to Treating Autoimmune Diseases by Modulating Immune Cell Proliferation

07129

PIKFYVE inhibitors boost Treg cells, curb Th17 differentiation, restoring immune balance to treat autoimmune diseases.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Neuroscience
Immunology
Therapeutic Indications: Multiple Sclerosis (MS)
Autoimmune encephalitis (AIE)
Tags: Autoimmune
Platform Technology
Personalized Medicine
Lead Inventor: William Hawse
Department: Med-Immunology
All Tech Innovators: William F. Hawse
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-03-27

Microneedle Array Delivery of Adenovirus Vectored Vaccines

05297

Microneedle arrays deliver adenovirus-vectored vaccines into skin, boosting immunogenicity and enabling universal, adjuvant-enhanced vaccination.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - Viral Vector
Therapeutic Areas: Dermatology
Infectious Disease
Lead Inventor: Louis Falo
Department: Med-Dermatology
All Tech Innovators: Geza Erdos
Louis D. Falo Jr
Andrea A. Gambotto M.D.
Date Submitted: 2020-04-08

TDP-43 Targeting Antibodies for Diagnosing Neurodegenerative Diseases

07105

Novel antibodies target TDP-43 for early, non-invasive diagnosis of AD, ALS, PD, FTD, and related conditions.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Neuroscience
Therapeutic Indications: Parkinson's Disease
Amyotrophic lateral sclerosis (ALS)
Alzheimer's Disease
Tags: In Vitro Diagnostic
Lead Inventor: Thomas Karikari
Department: Med-Psychiatry
All Tech Innovators: Thomas K. Karikari
Xuemei Zeng
Date Submitted: 2025-03-04

Novel Influenza D Virus Vaccine Strategy

06964

Single-cycle M-null IDV vaccine prompts strong immunity without disease, offering cross-species protection for cattle, swine, and humans.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - subunit, recombinant, polysaccharide, or conjugate
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Influenza
Tags: Life Science
Lead Inventor: Suresh V Kuchipudi
Department: GSPH-Infectious Diseases & Microbiology
All Tech Innovators: Suresh V Kuchipudi
Santhamani Ramasamy
Date Submitted: 2024-11-08

Microparticle-Based Regulatory T Cell Recruitment for Muscle Regeneration

07174

Recruit Treg-evoked immune modulation via PLGA/PEG microparticles releasing CCL22 to enhance acute muscle regeneration.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Musculoskeletal
Tags: Regenerative medicine
Sports medicine
Tissue engineering
Lead Inventor: Matthew Borrelli
Department: Chem/Petroleum Engineering
All Tech Innovators: Matthew Andrew Borrelli
Steven R. Little
Heth Turnquist
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-05-05
Collections: Cell & Gene Therapy
Regenerative Medicine

Bacteriophage Cocktail to Treat Achromobacter

06380

Five phages form a cocktail to broaden Achromobacter targeting, offering personalized, antibiotic-sparing therapy potential.

Technology Type: Therapeutic Modality
Technology Subtype: Bacteriophage
Therapeutic Areas: Respiratory
Infectious Disease
Therapeutic Indications: Other
Lead Inventor: Daria Van Tyne
Department: Med-Medicine
All Tech Innovators: Ghady Haidar
Daria N. Van Tyne
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2023-04-20

PROTAC treatment for HIV

06285

PROTACs selectively degrade HIV Nef, restoring immune recognition and suppressing HIV replication, aiming for reservoir clearance.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Lead Inventor: Thomas Smithgall
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Lori Ann Emert-Sedlak
Allen B. Reitz
Thomas E. Smithgall
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-02-06

Innovative Small Molecule for Zika Virus Neutralization

06214

CZV1-1: first nonpeptide Zika neutralization surrogate enabling highly specific, room-temperature diagnostics and research tools.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Zika
Lead Inventor: Donald Burke
Department: GSPH-Epidemiology
All Tech Innovators: Donald S. Burke
Priscila Mayrelle Da Silva Castanha
Ernesto Torres De Azeved Marques Jr
Date Submitted: 2022-11-14
Collections: Women's & Reproductive Health

Biased GPCR Ligands as a Therapeutic Intervention Strategy for Alzheimer's Disease

06184

Biased GPCR ligands selectively block β-arrestin signaling, reduce amyloid pathology, and preserve safety in Alzheimer's models.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Neuroscience
Therapeutic Indications: Alzheimer's Disease
Lead Inventor: Amantha Thathiah
Department: Med-Neurobiology
All Tech Innovators: Yunhong Huang
Amantha Thathiah
Date Submitted: 2022-10-05

Small Molecule Allosteric Modulators of Class B GPCRs in the PTHR and Method to Identify Them

05559

Structure-guided discovery yields four small-molecule negative allosteric modulators of PTHR, offering oral, targeted osteoporosis therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Endocrinology and Metabolic Diseases
Lead Inventor: Ieva Sutkeviciute
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Ivet Bahar
Pemra Doruker
Jiyoung Lee
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-11-19
Collections: Cardiometabolic
Women's & Reproductive Health

Intestinal Microbiome Modulation to Enhance Anti-Tumor Immunity

05545

FMT with anti-PD-1 reprograms gut microbiome to overcome resistance and boost melanoma immune response.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Oncology
Therapeutic Indications: Melanoma
Lead Inventor: Diwakar Davar
Department: Med-Medicine
All Tech Innovators: Diwakar Davar
Amiran Dzutsev
Giorgio Trinchieri
Date Submitted: 2020-11-01

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2

05391

Multivalent nanobody cocktails deliver ultra-highly potent, breath-stable SARS-CoV-2 neutralization, enabling rapid, inhalable therapeutic options.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - subunit, recombinant, polysaccharide, or conjugate
Therapeutic Areas: Infectious Disease
Lead Inventor: Yi Shi
Department: Med-Cell Biology
All Tech Innovators: Yi Shi
Yufei Xiang
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-05-30

Trabecular Meshwork Stem Cell Secretome for Treatment of Glaucoma

05099

Stem cell secretome from trabecular meshwork lowers intraocular pressure, preserves vision via non-invasive, scalable glaucoma treatment.

Technology Type: Therapeutic Modality
Technology Subtype: Protein
Therapeutic Areas: Ophthalmology
Therapeutic Indications: Glaucoma
Lead Inventor: Yiqin Du
Department: Department of Ophthalmology
All Tech Innovators: Yiqin Du
Ajay Kumar
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-08-27
Collections: Regenerative Medicine

Lung-Targeting Peptide to Deliver Diagnostic and Therapeutic Targets to the Lung

05084

Lung-targeting cell-penetrating peptides enable higher-transduction delivery of diagnostics and therapies directly to lung tissue.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Respiratory
Therapeutic Indications: Chronic Obstructive Pulmonary Disease (COPD)
Asthma
Acute respiratory failure
Tags: Platform Technology
Lead Inventor: Maliha Zahid
All Tech Innovators: Maliha Zahid
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-08-07

Protection of Small Intestine from Radiation by Genetically Engineered Probiotics

05065

Genetically engineered probiotics deliver IL-22/IFN-B to protect and repair the intestine from radiation damage.

Technology Type: Therapeutic Modality
Technology Subtype: Protein
Therapeutic Areas: Oncology
Gastroenterology
Therapeutic Indications: Other
Lead Inventor: Xichen Zhang
Department: Med-Radiation Oncology
All Tech Innovators: Michael W. Epperly Ph.D.
Joel S. Greenberger M.D.
Xichen Zhang
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2019-07-22
Collections: Women's & Reproductive Health

Novel Compounds to Inhibit TNF-Induced NF-κB Pathways

04864

Network-centric discovery yields two first-in-class small molecules selectively blocking TNF-induced NF-κB signaling, reducing off-target effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Tags: Autoimmune
Lead Inventor: Carlos Camacho
Department: Med-Computational and Systems Biology
All Tech Innovators: Carlos Jaime Camacho
Robin E C Lee
Date Submitted: 2019-01-22

Anti-ANGPTL3 Treatment for Cardiometabolic Disease

07575

Angptl3 inhibitors offer a targeted HFpEF therapy, linking heart-to-liver signaling to halt disease progression and improve metabolism.

Technology Type: Therapeutic Modality
Therapeutic Areas: Hepatology
Cardiovascular
Therapeutic Indications: Metabolic Associated Fatty Liver Disease (MAFLD)
Heart failure
Tags: Antibody - mAb
Drug Discovery - Target
Life Science
Lead Inventor: Iain Scott
Department: Med-Medicine
All Tech Innovators: Iain Scott
Date Submitted: 2026-04-27
Collections: Cardiometabolic

Novel Therapy for Sepsis

07388

A novel polypeptide YPD-203 targets sepsis-induced cytokine surges, reducing organ damage and improving survival in animal models.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Sepsis
Tags: Peptide
Drug Discovery - Target
Life Science
Lead Inventor: Yuanpu Di
All Tech Innovators: Yuanpu Di
Date Submitted: 2025-10-24

Small Molecule Drug for Targeting Resistant Prostate Cancer

07323

New class of nuclear AR-degrading small molecules (NARDs) selectively targets resistant prostate cancer by degrading AR in the nucleus.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Timothy James Casad
Joel B. Nelson
Zhou Wang
Date Submitted: 2025-09-02

Novel Therapy for Chondrocyte Aging and Osteoarthritis

07004

GATA4-targeting small molecule HCA42027 may restore aged chondrocyte repair, offering a potential disease-modifying OA therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Musculoskeletal
Therapeutic Indications: Heart failure
Atherosclerotic disease
Osteoarthritis
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Hang Lin
Department: Med-Orthopedic Surgery
All Tech Innovators: Olivia Grace Bartholomew
Kate Li
Hang Lin
Date Submitted: 2024-12-11
Collections: Cardiometabolic

New Permanent Treatment for Cerebral Aneurysms

06726

Injectable, ECM-derived embolic seals aneurysms permanently, integrating with tissue to avoid coils, recanalization, and retreatment.

Technology Type: Therapeutic Modality
Therapeutic Areas: Hematology
Lead Inventor: Seungil Kim
All Tech Innovators: Seungil Kim
William R. Wagner PhD
Date Submitted: 2024-04-25
Collections: Regenerative Medicine

Novel Research Tool to Study TDP-43 Dysfunction

06637

CUTS-1 RNA biosensor flags TDP-43 dysfunction cells, enabling real-time disease tracking and targeted ALS/FTD/AD therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - RNA
Therapeutic Areas: Neuroscience
Therapeutic Indications: Alzheimer's Disease
Lead Inventor: Christopher Donnelly
Department: Med-Neurobiology
All Tech Innovators: Christopher James Donnelly
Date Submitted: 2024-02-08
Collections: Cell & Gene Therapy

Targeted HDAC 8 Inhibitors for Managing Kidney Disease

06617

Indole-based HDAC-8 inhibitors offer targeted, potentially less toxic kidney disease therapy; prototype-stage, organoid-supported efficacy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Nephrology
Therapeutic Indications: Acute Kidney Injury (AKI)
Lead Inventor: Donna Huryn
All Tech Innovators: Neil A. Hukriede
Donna Huryn
Sangeetha Subramani
Date Submitted: 2024-01-26

Novel Use of Metformin to Treat Musculoskeletal Injury

06416

Metformin advances tendon healing by reducing fibrosis and inflammation, promoting angiogenesis for safer, cost-effective tendinopathy treatment.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Neuroscience
Musculoskeletal
Lead Inventor: James Wang
Department: Med-Orthopedic Surgery
All Tech Innovators: James Huicong Wang
Jianying Zhang
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-05-23
Collections: Regenerative Medicine

Novel Glutamate Receptor Agonists

06272

Glutamate receptor agonist SYM2081 dampens dermal mast cell activation, offering potential treatments for dermatitis, rosacea, and hypersensitivity.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Dermatology
Therapeutic Indications: Dermatitis
Lead Inventor: Daniel Kaplan
Department: Med-Dermatology
All Tech Innovators: Daniel H. Kaplan
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2023-01-24

Novel Approach to Reverse Cerebral Cortex Decline

06081

Proteins linked to aging spine loss identified; 10 drugs may protect cognition, slowing dementia by preserving dendritic spines.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Neuroscience
Therapeutic Indications: Dementia
Alzheimer's Disease
Tags: Aging
Drug Repurposing
Lead Inventor: Robert Sweet
Department: Med-Psychiatry
All Tech Innovators: Peihao Fan
Joshua Michael Krivinko
Matthew Luke MacDonald
Date Submitted: 2022-06-30

Novel Nucleotide Prodrugs to Target Oxidative Stress

05934

Targeted oxidative-stress-activated nucleotide prodrugs release active nucleotides in diseased tissue, enabling safer cancer/antiviral therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - DNA
Therapeutic Areas: Infectious Disease
Oncology
Lead Inventor: Paul Floreancig
Department: Chemistry
All Tech Innovators: Alexander Deiters
Paul Edward Floreancig
Brittany M. Klootwyk
Date Submitted: 2022-01-05
Collections: Cell & Gene Therapy

NAMPT Inhibitors Exhibit Excellent Potency and ADME Properties

05522

Novel Nampt inhibitors deliver strong potency and favorable ADME, enabling chemotherapy and immune support benefits.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Immunology
Oncology
Tags: Autoimmune
Immuno-oncology
Lead Inventor: Beibei Chen
Department: Med-Medicine
All Tech Innovators: Beibei Chen
Toren Finkel
Yuan Liu
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-10-06

Humanized Animal Models for Advanced Antibody Production

04301

Humanized mice cultivate human immune responses to produce monoclonal antibodies, enabling safer, more efficacious human antibody therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Other
Tags: Platform Technology
Lead Inventor: Moses Bility
Department: GSPH-Infectious Diseases & Microbiology
All Tech Innovators: Moses Turkle Bility
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2017-06-21

Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress

03916

Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Lead Inventor: Peter Wipf
Department: Chemistry
All Tech Innovators: Hulya Bayir
Robert B. Clark
Tanja Krainz
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2016-04-23

Biodegradable Poly(Ester Amide) Elastomers

03590

Biodegradable poly(ester amide) elastomers: solvent-free, tunable, biocompatible scaffolds for soft tissue engineering and drug delivery.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Tags: Polymer
Platform Technology
Lead Inventor: Shilpa Sant
Department: Department of Pharmaceutical Sciences
All Tech Innovators: Shilpa Sant
Vinayak Sant
Date Submitted: 2015-04-20
Collections: Regenerative Medicine

AAV-Based Mitochondrial Gene Therapy: A Novel Approach to Slowing Neurodegeneration

07363

AAV-TIMs neurons: brain-wide delivery of TIM17/23/50 to restore mitochondrial import, slowing neurodegeneration across HD and beyond.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - AAV
Therapeutic Areas: Neuroscience
Therapeutic Indications: Parkinson's Disease
Huntington's Disease
Amyotrophic lateral sclerosis (ALS)
Tags: Genetics
Rare disease
Platform Technology
Lead Inventor: Robert Friedlander
Department: Med-Neurological Surgery
All Tech Innovators: Sergei Victorovich Baranov
Diane L. Carlisle
Robert Max Friedlander
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2025-10-06
Collections: Cell & Gene Therapy

Regenerative Topical Therapy for Cold-Induced Skin Injury: A Field-Ready Solution to Prevent Necrosis and Amputation

07296

Hydrogel HA-Metformin topical therapy accelerates frostbite healing, restores skin adnexa, reduces inflammation, and lowers amputation risk.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Dermatology
Tags: Biomaterial
Polymer
Regenerative medicine
Lead Inventor: James Wang
Department: Med-Orthopedic Surgery
All Tech Innovators: James Huicong Wang
Jianying Zhang
Technology Readiness Level: 5. Drug candidate created
Date Submitted: 2025-08-19
Collections: Regenerative Medicine

Novel Repair and Regeneration Therapy for Glaucoma

07246

AAV-Ina overexpression promotes retinal ganglion cell survival and axon regeneration, offering neuroprotection for glaucoma with regeneration potential.

Technology Type: Therapeutic Modality
Therapeutic Areas: Neuroscience
Ophthalmology
Therapeutic Indications: Glaucoma
Tags: Drug Discovery - Target
Life Science
Lead Inventor: Kun Che Chang
Department: Med-Ophthalmology
All Tech Innovators: Kun Che Chang
Chi-Yu Chen
Date Submitted: 2025-07-11

A Novel Platform for Enhanced Inner Ear Drug Delivery and Gene Therapy

07230

Exosome-based inner ear drug delivery platform enhances RWM traversal, enabling sustained, versatile loading of drugs and gene therapies.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Otolaryngology
Therapeutic Indications: Hearing Loss
Tags: Regenerative medicine
Platform Technology
Lead Inventor: Adele Moatti
Department: Med-Otolaryngology
All Tech Innovators: Adele Moatti
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-06-23
Collections: Regenerative Medicine

AAV Potentiator Polypeptides: Unlocking Deeper Tissue Penetration for Next-Generation Gene Therapy

07037

Potentiator polypeptides boost AAV tissue penetration, enabling lower doses and broader gene therapy applications across organs.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - AAV
Therapeutic Areas: Oncology
Ophthalmology
Therapeutic Indications: Other
Retinitis pigmentosa (RP)
Age-related macular degeneration
Tags: Genetics
Platform Technology
Lead Inventor: Miguel Betegon
Department: Med-Ophthalmology
All Tech Innovators: Miguel Betegon
Leah Caroline Thomas Byrne
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-01-20
Collections: Cell & Gene Therapy

Borylated Esters and Acetals as Cancer Prodrugs

06731

Boronate-protected prodrugs release cytotoxins in peroxide-rich cancer cells, enabling targeted, reduced-side-effect chemotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Oncology
Tags: Life Science
Lead Inventor: Paul Floreancig
Department: Chemistry
All Tech Innovators: Alexander Deiters
Paul Edward Floreancig
Paul Joseph Geaneotes
Date Submitted: 2024-04-29

Novel Neutralizing Nanobodies for Coronavirus Diseases

05802

Pan-sarbecovirus nanobodies enable inhalable, stable, cost-effective COVID-19 and related coronavirus neutralization across variants.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Other
Covid-19
Lead Inventor: Yi Shi
Department: Med-Cell Biology
All Tech Innovators: Yi Shi
Yufei Xiang
Date Submitted: 2021-09-06

A Novel Method to Improve Adoptive Cell Therapy

05447

Redirects T cell glucose metabolism with dichloroacetate to boost mitochondrial health, viability, and antitumor activity in adoptive cell therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Cell Therapy - T Cell
Therapeutic Areas: Oncology
Lead Inventor: Greg Delgoffe
Department: Med-Immunology
All Tech Innovators: Greg M. Delgoffe
Andrew Tyler Frisch
Date Submitted: 2020-07-16
Collections: Cell & Gene Therapy

Neuroprotective Peptide in Acute Ischemic Injury

05442

A brain-penetrant peptide (TAT-DP-2) disrupts Kv2.1 clusters to prevent delayed neuronal death after stroke.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Cardiovascular
Neuroscience
Therapeutic Indications: Stroke
Other
Lead Inventor: Elias Aizenman
Department: Med-Neurobiology
All Tech Innovators: Elias Aizenman
Jason Arnold Justice
Anthony John Schulien
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2020-07-09
Collections: Cardiometabolic

Insertion Unique to SARS-CoV-2 Exhibits Superantigenic Characteristics

05404

SARS-CoV-2 spike contains a unique superantigen-like site; monoclonal antibodies may block MIS-C, cytokine storms, and entry.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Infectious Disease
Therapeutic Indications: Covid-19
Lead Inventor: Ivet Bahar
Department: Biochemistry and Cell Biology
All Tech Innovators: Moshe Arditi MD
Ivet Bahar
Hongying Cheng
Date Submitted: 2020-06-05

Enhanced Antitumor Efficacy of Ultrasound-mediated Doxorubicin Delivery by Microbubble-liposome Complex

05168

Ultrasound-triggered microbubble-liposome delivery of doxorubicin enhances tumor kill, reduces cardiotoxicity, boosting soft-tissue sarcoma therapy.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Delivery / Formulation
Therapeutic Areas: Oncology
Therapeutic Indications: Solid tumor
Lead Inventor: Flordeliza Villanueva
Department: Med-Medicine
All Tech Innovators: Xucai Chen
Mingyu He
Flordeliza S. Villanueva M.D.
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-11-14

Microsphere-Based Therapy for Reversing New-Onset Autoimmune Diabetes

01703

Innovative antisense-loaded microspheres reverses new-onset autoimmune diabetes by downregulating CD40/CD80/CD86, modulating dendritic cells.

Technology Type: Therapeutic Modality
Technology Subtype: Vaccine - subunit, recombinant, polysaccharide, or conjugate
Therapeutic Areas: Endocrinology and Metabolic Diseases
Therapeutic Indications: Diabetes
Lead Inventor: Nick Giannoukakis
Department: Med-Pathology
All Tech Innovators: Nick Giannoukakis
Massimo M. Trucco
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2008-04-17
Collections: Cardiometabolic

Novel EGFR Tumor-Associated Antigens and Enhanced Agonist Epitopes

01638

Novel EGFR tumor antigens and potent agonist epitopes enable enhanced immunotherapy and vaccines for EGFR-expressing cancers.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Oncology
Therapeutic Indications: Nasopharyngeal carcinoma (NPC)
Solid tumor
Other
Tags: Immuno-oncology
Lead Inventor: Robert Ferris
All Tech Innovators: Pedro Alcantara Andrade
Robert Louis Ferris
Andres Lopez Albaitero
Technology Readiness Level: 6. IND-enabling studies
Date Submitted: 2008-02-11

Targeted Anodal Stimulation for Spinal Grey Matter: Precision Motor Recovery

07374

Targeted intra-spinal anodal stimulation activates motor neuron somata for precise hand and limb recovery, compatible with neuroprosthetics.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Neuroscience
Therapeutic Indications: Multiple Sclerosis (MS)
Tags: Platform Technology
Lead Inventor: Evan Rogers
Department: Med-Neurological Surgery
All Tech Innovators: Marco Capogrosso
Evan R. Rogers
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2025-10-20

A Novel Mechanism for Disrupting Biofilms and Combating Antimicrobial Resistance

07134

Disrupts bacterial biofilms by targeting wall teichoic acid with WLBU2; low-probability resistance via membrane potential changes.

Technology Type: Therapeutic Modality
Technology Subtype: Peptide
Therapeutic Areas: Infectious Disease
Tags: Coating
Drug Discovery - Target
Lead Inventor: Kenneth Urish
Department: Med-Orthopedic Surgery
All Tech Innovators: Umit Akbey
Vaughn Scott Cooper
Kenneth L. Urish Jr
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-04-02

Targeting Cardiomyocyte Endoreplication to Prevent Hypertrophic Cardiomyopathy

07132

Inhibits PCNA-POLD1 interactions via p21 to curb cardiomyocyte endoreplication, preventing hypertrophic cardiomyopathy progression.

Technology Type: Therapeutic Modality
Technology Subtype: Gene Therapy - RNA
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Hypertrophic cardiomyopathy
Tags: Genetics
Regenerative medicine
Platform Technology
Lead Inventor: Jason Becker
Department: Med-Medicine
All Tech Innovators: Jason Robert Becker
Soumojit Pal
Technology Readiness Level: 4. Pre-clinical development
Date Submitted: 2025-03-30
Collections: Cell & Gene Therapy
Cardiometabolic

HIF1 Activators as Therapeutics for Triosephosphate Isomerase Deficiency (TPI Df)

07001

HIF1-activating triazines boost TPI expression, repurposing approved PHD inhibitors (e.g., vadadustat) for TPI deficiency.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Musculoskeletal
Lead Inventor: Michael Palladino
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Michael John Palladino
Andreas Vogt
Date Submitted: 2024-12-09

Nitro-fatty Acids for Treating Aortic Aneurysm

05302

Nitro-oleic acid (nitro-fatty acid) shows promise halting abdominal aortic aneurysm progression via anti-inflammatory effects.

Technology Type: Therapeutic Modality
Technology Subtype: Small Molecule
Therapeutic Areas: Cardiovascular
Therapeutic Indications: Other
Lead Inventor: Francisco Schopfer
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Yuqing Eugene Chen
Bruce A. Freeman
Francisco Jose Schopfer PhD
Date Submitted: 2020-04-13
Collections: Cardiometabolic

Use of Specific Phages for the Treatment of Non-Tuberculosis Mycobacterial Infections

05095

Phage therapy targets drug-resistant non-tuberculous Mycobacteria, enabling rapid, strain-specific treatment with minimal resistance and side effects.

Technology Type: Therapeutic Modality
Technology Subtype: Bacteriophage
Therapeutic Areas: Respiratory
Infectious Disease
Tags: Biomaterial
Lead Inventor: Graham Hatfull
Department: Distinguished Faculty-Dietrich School of Arts and Sciences
All Tech Innovators: Rebekah Marie Dedrick
Carlos Andres Guerrero
Graham F. Hatfull
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2019-08-20